Corroborating this idea, immune checkpoint inhibitors including anti-PD-1 agents have emerged as successful anti-cancer therapies for a subset of patients, which indicates that a PD-1 positive immune environment contributes to cancer [18]. This evidence concerns the gene PDCD1 and cancer.